Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
Osimertinib Study in Indian Patients
- Status
- COMPLETED
- Phase
- PHASE4
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
- Status
- COMPLETED
- Phase
- PHASE2
First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive
- Status
- COMPLETED
- Phase
- N/A
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2